Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dual-target CAR T cells C-4-29

A preparation of human T lymphocytes that have been genetically modified to express a dual-target CAR, with potential immunostimulating and antineoplastic activities. Upon administration, the dual-target CAR T cells C-4-29 recognize and kill tumor cells expressing the two as of yet undisclosed targets. This results in a cytotoxic T-lymphocyte (CTL) response against these tumor cells, thereby causing tumor cell lysis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	C-4-29

dual-target CAR T cells C-4-29

Search NCI's Drug Dictionary